Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
October-2017 Volume 14 Issue 4

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
October-2017 Volume 14 Issue 4

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article Open Access

miR-21 inhibition of LATS1 promotes proliferation and metastasis of renal cancer cells and tumor stem cell phenotype

  • Authors:
    • Feng An
    • Yidong Liu
    • Yan Hu
  • View Affiliations / Copyright

    Affiliations: Department of Urinary Surgery, Affiliated Hospital of Hebei University, Baoding, Hebei 071000, P.R. China, Department of Urinary Surgery, Taian City Central Hospital, Taian, Shandong 271000, P.R. China
    Copyright: © An et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Pages: 4684-4688
    |
    Published online on: August 10, 2017
       https://doi.org/10.3892/ol.2017.6746
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

MicroRNA (miR)-21 has many regulatory functions in the cell, including activities in cancer cells and cancer stem cells. Large tumor suppressor gene 1 (LATS1) is a target of miR‑21 that could mediate several of these phenotypes. This study explored the effect of miR‑21 silencing in renal cancer cell function and LATS1 expression. Silencing of miR‑21 in Caki‑2 cells reached an efficiency of 55‑60%. This was sufficient to detect decrease in Caki‑2 cell proliferation and migration invasion capacity. miR‑21 silencing increased LATS1 expression at both mRNA and protein levels. The number of tumor spheres formed by cells expressing si‑miR‑21 was significantly reduced and the expression of tumor stem cell markers Nanog and CT3/4 were significantly downregulated. miR‑21 seems to regulate LATS1 expression in renal cancer Caki‑2 cells, resulting in reduced proliferation, invasion, and cancer stem cell phenotype. miR‑21 may promote malignant phenotype of tumor cells through LATS1 silencing, which can be regarded as a new target candidate gene for renal cancer treatment.

Introduction

Renal cell carcinoma (RCC) originates from the malignant tumor of the epithelium system of urinary tubule of renal parenchyma. RCC has become the malignant tumor with the highest mortality in the urinary system, accounting for 2–3% of adult malignant tumors (1,2). The incidence of RCC shows an upward trend each year, ranking 10 in the incidence rate of male malignant tumors in China in 2008. The causes and pathogenesis of RCC are still unclear.

MicroRNAs (miRs) are non-coding, small RNAs 19–25 nucleotides long. The function of miRs is mainly to degrade mRNA of target genes through binding to the 3′ untranslated region (3), thereby regulating the expression and function of downstream genes. miRs participate in the regulation of development, cell apoptosis, proliferation and differentiation and other fundamental cell biology activities (4,5). In recent years it was discovered that many miRs play an important role in the development of tumors such as proto-oncogenes or tumor suppressor genes. Among them miR-21 is the most prominent. Experimental results suggest that in most of the tumors, such as malignant glioma, breast cancer, bile duct cancer, pancreatic cancer, lung cancer, rectal cancer, bladder cancer, kidney cancer, and esophageal cancer, the expression of miR-21 is significantly increased (6–14) indicating that miR-21 plays an important role in the development of tumors.

The Hippo signaling pathway is an evolutionarily conserved regulator of cell growth inhibition. In mammals, when the receptor receives the growth inhibitory signals, it will phosphorylate downstream effectors YAP after the phosphorylation cascade reaction of a series of kinase complexes. Phosphorylated YAP interacts with cytoskeletal proteins, is retained in the cytoplasm and cannot enter the nucleus to exercise transcriptional activation, thus regulating organ size and volume. In addition, recent studies have confirmed the Hippo signaling pathway is also involved in the regulation of cancer, tissue regeneration, and the function of stem cells. Large tumor suppressor gene 1 (LATS1) binds and phosphorylates YAP1 in vitro and in vivo, affecting its transcription regulation (15,16). Studies show that low expression of LATS1 can lead to the occurrence of astrocytoma, breast cancer, head and neck squamous cell carcinoma, colorectal cancer, cervical cancer, gastric cancer, skin cancer, metastatic prostate cancer, and RCC (17–25). Some studies propose that miR-21 can resist radiation therapy by inhibiting the expression of LATS1 in ovarian cancer cells (26). LATS1 mRNA may be a direct target of miR-21 and the relationship between miR-21 and LATS1 in RCC has not been reported yet. This study used small interfering RNA (siRNA) to silence miR-21 expression in RCC Caki-2 cells. We also observed the role of miR-21 in renal carcinoma cell proliferation and invasion, and tumor stem cell phenotype to help understand miR-21 function and its targets.

Materials and methods

Cell line and main reagents

Human renal carcinoma Caki-2 cells were from American Type Culture Collection (ATCC; Manassas, VA, USA), Dulbecco's modified Eagle's medium (DMEM) culture and fetal bovine serum from Gibco Life Technologies (Carlsbad, CA, USA), methyl thiazolyl tetrazolium (MTT) kit from Sigma (St. Louis, MO, USA), miR isolation extraction and separation kit, RPMI-1640, Lipofectamine® 2000 and TRIzol from Invitrogen Life Technologies (Carlsbad, CA, USA). The quantitative (qPCR) (qPCR) Mix kits were from Takara Bio, Inc. (Otsu, Japan) and mouse monoclonal LATS1 antibody (dilution, 1:500; cat. no. sc-398560), mouse monoclonal Nanog antibody (dilution, 1:500; cat. no. sc-293121), mouse monoclonal OCT3/4 (dilution, 1:500; cat. no. sc-5279), and mouse monoclonal GAPDH antibody (dilution, 1:500; cat. no. sc-293335) were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Primers were designed and synthesized by Shanghai Jima Pharmaceutical Technology Co., Ltd. (Shanghai, China). si-miR-21 and si-negative control were synthesized by Shanghai Jima Pharmaceutical Technology. si-miR-21 forward, 5′-GATCCAUCUTCGAAGUGACTT-3′ and reverse, 5′-UGCUCUTUGACGUAUGGAGTT-3′; si-negative control forward, 5′-UUCACCGUACGUCUCACCUGT-3′ and reverse, 5′-ACUGGAACCUCUCGCGGAATT-3′; LATS1 forward, 5′-AAATGCCCACATCCGGGAAA-3′ and reverse, 5′-ACCTGGCTCTCCCCTTAACA-3′.

si-miR-21 and si-negative control transfection of Caki-2 cells

The cells in the logarithmic growth phase were divided into three groups based on treatment: miR-21, si-miR-21, and si-negative control. When the cell fusion reached 80–90%, transfection was conducted with Lipofectamine® 2000 according to instructions. At 48 h after transfection, miR was extracted following the manufacturer's instructions. We used light photometer to detect RNA absorbance and calculate RNA concentration and purity. The samples with a rate from 1.8 to 2.1 were selected for further experiments. qPCR was used to conduct comparative analysis of miR-21 mRNA in Caki-2 in the three groups after transfection.

qPCR

Total RNA was extracted from the three groups and purified according to the TRIzol kit instructions; 1 µg RNA template was converted into cDNA by reverse transcription according to reverse transcription kit. The reaction system was 10 µl, at 37°C for 15 min and heated at 85°C for 30 sec. The amplification condition was: 95°C for 5 min, then 95°C for 30 sec, 58°C for 30 sec, 72°C for 30 sec, a total of 30 cycles, and finally 72°C for 5 min. Analysis of dissolution curve was conducted after the reaction.

Western blotting

Total protein from cells of the three groups was extracted by RIPA lysis solution plus 1% PMSF, and the protein concentration was detected by BCA (all from Biosharp, Hefei, China). A 1/4 volume of the protein sample buffer was added, denatured at 100°C for 10 min. SDS-polyacrylamide separating gel (Keygen, Nanjing, China) and stacking gel were prepared, Tris glycine electrophoretic buffer solution and equal amount of denatured protein of ~50 µg per well were added, proteins were transferred to PVDF membrane after electrophoresis and blocked in 3% BSA for 2 h. Primary antibodies (anti-LATS1 1:1,000; anti-GAPDH 1:1,000) were added at 4°C overnight, TBST membrane was washed 3 times/10 min, then horseradish peroxidase-labeled secondary antibodies (1:5,000) were added at 37°C for 2 h, TBST membrane was washed 3 times/10 min, ECL development, and development in vilber lourmat in the dark.

Proliferation assay by MTT

Cells from each group were inoculated in 96-well culture plate at a density of 2×103 cells/well. Three multiple pores were set and 2 ml of 5 mg/ml MTT was added to each pore after 24, 48, 72, 96 and 120 h. They were incubated for 4 h, then the supernatant was discarded, 150 µl of DMSO was added, mixed, dissolved and crystallized. The light density value [D (490)] in each pore was determined at 490 nm wavelength, and cell proliferation inhibitory rate (IR): was calculated IR = [1-experimental group D (490)/the control group D (490)] × 100.

Invasion ability of Caki-2 cells by Transwell

Experiments were conducted according to the BioCoat Matrigel invasion chamber kit instructions. Eight different visual fields (magnification, ×100) were counted under the microscope, repeating 3 times, and the percentage of the invasion cells was calculated.

Tumor sphere formation

Serum-free medium (SFM) was prepared with Ham's DMEM-F12 (1:1), B27 (1:50), EGF (20 mg/ml), and bFGF (20 ng/ml). The cells of the three groups were inoculated in DMEM with 10% fetal bovine serum until the cells were in the logarithmic growth phase, and they were washed with PBS, digested with 0.25% trypsin, and washed in PBS twice after digestion. Then the cells were placed in the low adhesion culture in suspension for 48 h and changes in cell morphology were observed under an inverted microscope. The formation of tumor spheres was observed and the numbers of tumor spheres were counted after 14 days.

Statistical analysis

SPSS 19.0 software (SPSS, Inc., Chicago, IL, USA) was used for plotting and statistical analysis, measurement data are expressed by mean ± standard deviation, comparison of rate was tested by χ2, GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA) was used to carry out one-way ANOVA analysis and plotting for qPCR results, P<0.05 was considered to indicate a statistically significant difference.

Results

Efficiency of siRNA transfection by qPCR

According to qPCR, transfection of Caki-2 cells with si-miR-21 resulted in significant reduction of miR-21 compared to transfection with si-negative control (F=71.90, P<0.05). The silencing efficiency was 55–60% (Fig. 1).

Figure 1.

miR-21 mRNA expression after transfection detected by qRT-PCR. *P<0.05.

LATS1 expression after transfection of miR-21 knockdown

Western blot analysis showed that the expression level of LATS1 protein was significantly higher in cells transfected with si-miR-21 compared to control cells and si-negative cells (Fig. 2A). qPCR showed that LATS1 mRNA expression was significantly higher in cells transfected with si-miR-21 compared to control and si-negative cells (F=108.5, P<0.05; Fig. 2B).

Figure 2.

LAST1 expression by western blotting and qRT-PCR. (A) LAST1 expression after transfection detected by western blotting. (B) LAST1 expression at mRNA level after transfection detected by qRT-PCR. *P<0.05.

Proliferation of Caki-2 cells after miR-21 silencing

Following cell transfection, we collecting cell number data at 1, 24, 48, 72, 96 and 120 h. We found no significant differences at 24 and 48 h, but si-miR-21 showed lower proliferation after 72 h (Fig. 3). The proliferation rate at 72 h was: 40.5±11.6% for si-miR-21, 57.4±5.9% for si-negative control, and 58.3±4.3% for non-transfected control (t=2.375, P<0.05). Cell proliferation at 96 h was: 43.7±12.5% for si-miR-21, 75.6±7.5% for si-negative control, and 78.3±6.9% for non-transfected control (t=4.587, P<0.01). Cell proliferation at 120 h was: 48.9±12.3% for si-miR-21, 81.9±4.6% for si-negative control, and 85.2±3.8% for non-transfected control (t=5.698, P<0.01). Thus, si-miR-21 intervention inhibited the proliferation capacity of Caki-2 cells.

Figure 3.

Caki-2 proliferation after transfection detected by MTT. *P<0.05, **P<0.01.

Caki-2 cell invasion after si-miR-21 transfection

The invasion ability of Caki-2 cells transfected with si-miR-21 significantly decreased compared to the si-negative control cells and the non-transfected cells (F=135.1, P<0.01; Fig. 4). Thus, miR-21 knockdown reduces the invasivity of Caki-2 cells.

Figure 4.

(A and B) Detection of invasion ability after transfection. *P<0.05.

Tumor sphere formation

Compared to the si-negative control cells and the non-transfected cells, the number of Caki-2 cells forming tumor spheres significantly decreased in cells transfected with si-miR-21 (F=46.17, P<0.05; Fig. 4).

Phenotype of cancer stem cells

Last, we examined the ability of miR-21 to regulate the stem cell characteristics of Caki-2 cells. For this, we determined the expression of the stem cell markers, OCT3/4 and Nanog. Caki-2 cells transfected with si-miR-21 showed significantly decreased levels of OCT3/4 and Nanog compared to the si-negative control cells and the non-transfected cells (Fig. 5). These results suggest a role for miR-21 in the regulation of the stem cell state and the transformation into tumorous state.

Figure 5.

miR-21 regulation of stem cell qualities. (A) Tumor sphere formation. (B) Western blotting detection of OCT3/4 and Nanog. *P<0.05.

Discussion

miRs are endogenous regulatory molecules that play roles as oncogenes or tumor suppressor genes in the development of tumors. As one of the most studied miRs in recent years, miR-21 is highly expressed in gastric cancer, breast cancer, colon cancer, and other tumors, and can be used as a marker to determine the prognosis of various tumors. Some studies suggest that miR-21 overexpression downregulate LATS1 expression. A large number of studies have found that as one of the key factors in the hippo-Yap signaling pathway, LATS1 expression is reduced in a variety of tumors, which may be related to the high expression of miR-21 (27–29).

Here we showed that silencing miR-21 in Caki-2 cells decreased the proliferation ability after 72 h and continued to decrease until 120 h. Downregulation of miR-21 also resulted in elevated LATS1 expression, indicating that miR-21 has a regulatory effect on the expression of LATS1. miR-21 is known to regulate cell differentiation, proliferation, development, apoptosis, metabolism and cancerous transformation (30).

Tumor stem cells have self-renewal capacity and can produce heterogeneous tumor cells. They can sustain the vitality of the tumor cell population through self-renewal, unlimited proliferation, movement, and migration ability to promote the transfer of tumor cells. Cancer stem cells can be in a dormant state for a long time and are insensitive to a variety of chemotherapeutic drugs and external physicochemical factors killing tumors, resulting in antitumor drug resistance and reducing the treatment effect. To clarify the mechanism regulating tumor stem cell state is very important for the treatment of tumors. This study found that downregulation of miR-21 inhibited the phenotype of tumor stem cells.

Our study results show that silencing miR-21 expression inhibited the malignant activities of renal carcinoma cells. This inhibition may be induced by downregulation of LATS1 expression and miR-21 may be seen as a marker for diagnosis and prognostic analysis of RCC and LATS1 may become a new target for treatment.

References

1 

Creighton CJ, Morgan M, Gunaratne PH, Wheeler DA, Gibbs RA, Robertson Gordon A, Chu A, Beroukhim R, Cibulskis K, Signoretti S, et al: Cancer Genome Atlas Research Network: Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar : PubMed/NCBI

2 

Junker K, Ficarra V, Kwon ED, Leibovich BC, Thompson RH and Oosterwijk E: Potential role of genetic markers in the management of kidney cancer. Eur Urol. 63:333–340. 2013. View Article : Google Scholar : PubMed/NCBI

3 

Silahtaroglu A and Stenvang J: MicroRNAs, epigenetics and disease. Essays Biochem. 48:165–185. 2010. View Article : Google Scholar : PubMed/NCBI

4 

Ross SA and Davis CD: MicroRNA, nutrition, and cancer prevention. Adv Nutr. 2:472–485. 2011. View Article : Google Scholar : PubMed/NCBI

5 

Nimmo RA and Slack FJ: An elegant miRror: microRNAs in stem cells, developmental timing and cancer. Chromosoma. 118:405–418. 2009. View Article : Google Scholar : PubMed/NCBI

6 

Chan JA, Krichevsky AM and Kosik KS: MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65:6029–6033. 2005. View Article : Google Scholar : PubMed/NCBI

7 

Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI

8 

Selaru FM, Olaru AV, Kan T, David S, Cheng Y, Mori Y, Yang J, Paun B, Jin Z, Agarwal R, et al: MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology. 49:1595–1601. 2009. View Article : Google Scholar : PubMed/NCBI

9 

Dillhoff M, Liu J, Frankel W, Croce C and Bloomston M: MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg. 12:2171–2176. 2008. View Article : Google Scholar : PubMed/NCBI

10 

Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, Alattar M, Deepak J, Stass SA and Jiang F: Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer. 67:170–176. 2010. View Article : Google Scholar : PubMed/NCBI

11 

Rossi L, Bonmassar E and Faraoni I: Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro. Pharmacol Res. 56:248–253. 2007. View Article : Google Scholar : PubMed/NCBI

12 

Neely LA, Rieger-Christ KM, Neto BS, Eroshkin A, Garver J, Patel S, Phung NA, McLaughlin S, Libertino JA, Whitney D, et al: A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol. 28:39–48. 2010. View Article : Google Scholar : PubMed/NCBI

13 

Lv L, Huang F, Mao H, Li M, Li X, Yang M and Yu X: MicroRNA-21 is overexpressed in renal cell carcinoma. Int J Biol Markers. 28:201–207. 2013. View Article : Google Scholar : PubMed/NCBI

14 

Feber A, Xi L, Luketich JD, Pennathur A, Landreneau RJ, Wu M, Swanson SJ, Godfrey TE and Litle VR: MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg. 135:255–260; discussion 260. 2008. View Article : Google Scholar : PubMed/NCBI

15 

Mo JS, Park HW and Guan KL: The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 15:642–656. 2014.PubMed/NCBI

16 

Harvey K and Tapon N: The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat Rev Cancer. 7:182–191. 2007. View Article : Google Scholar : PubMed/NCBI

17 

Jiang Z, Li X, Hu J, Zhou W, Jiang Y, Li G and Lu D: Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res. 56:450–458. 2006. View Article : Google Scholar : PubMed/NCBI

18 

Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y and Noguchi S: Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res. 11:1380–1385. 2005. View Article : Google Scholar : PubMed/NCBI

19 

Steinmann K, Sandner A, Schagdarsurengin U and Dammann RH: Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. Oncol Rep. 22:1519–1526. 2009.PubMed/NCBI

20 

Wierzbicki PM, Adrych K, Kartanowicz D, Stanislawowski M, Kowalczyk A, Godlewski J, Skwierz-Bogdanska I, Celinski K, Gach T, Kulig J, et al: Underexpression of LATS1 TSG in colorectal cancer is associated with promoter hypermethylation. World J Gastroenterol. 19:4363–4373. 2013. View Article : Google Scholar : PubMed/NCBI

21 

Visser S and Yang X: Identification of LATS transcriptional targets in HeLa cells using whole human genome oligonucleotide microarray. Gene. 449:22–29. 2010. View Article : Google Scholar : PubMed/NCBI

22 

Zhou GX, Li XY, Zhang Q, Zhao K, Zhang CP, Xue CH, Yang K and Tian ZB: Effects of the hippo signaling pathway in human gastric cancer. Asian Pac J Cancer Prev. 14:5199–5205. 2013. View Article : Google Scholar : PubMed/NCBI

23 

Nishio M, Hamada K, Kawahara K, Sasaki M, Noguchi F, Chiba S, Mizuno K, Suzuki SO, Dong Y, Tokuda M, et al: Cancer susceptibility and embryonic lethality in Mob1a/1b double-mutant mice. J Clin Invest. 122:4505–4518. 2012. View Article : Google Scholar : PubMed/NCBI

24 

Zhao B, Li L, Wang L, Wang CY, Yu J and Guan KL: Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 26:54–68. 2012. View Article : Google Scholar : PubMed/NCBI

25 

Chen KH, He J, Wang DL, Cao JJ, Li MC, Zhao XM, Sheng X, Li WB and Liu WJ: Effects of LATS1 gene methylation on biological function in human renal cell carcinoma and Hippo-YAP signaling pathway. J Third Mil Med Univ. 36:1249–1254. 2014.

26 

Liu S, Song L, Zhang L, Zeng S and Gao F: miR-21 modulates resistance of HR-HPV positive cervical cancer cells to radiation through targeting LATS1. Biochem Biophys Res Commun. 459:679–685. 2015. View Article : Google Scholar : PubMed/NCBI

27 

Teteloshvili N, Smigielska-Czepiel K, Yuan Y, Seitz A, de Jong D, Rutgers B, Jellema P, van der Lei RJ, Slezak-Prochazka I, Brouwer E, et al: Argonaute 2 immunoprecipitation revealed large tumor suppressor kinase 1 as a novel proapoptotic target of miR-21 in T cells. FEBS J. 284:555–567. 2017. View Article : Google Scholar : PubMed/NCBI

28 

Liu S, Song L, Zhang L, Zeng S and Gao F: miR-21 modulates resistance of HR-HPV positive cervical cancer cells to radiation through targeting LATS1. Biochem Biophys Res Commun. 459:679–685. 2015. View Article : Google Scholar : PubMed/NCBI

29 

Xia H, Qi H, Li Y, Pei J, Barton J, Blackstad M, Xu T and Tao W: LATS1 tumor suppressor regulates G2/M transition and apoptosis. Oncogene. 21:1233–1241. 2002. View Article : Google Scholar : PubMed/NCBI

30 

Chen J and Wang X: MicroRNA-21 in breast cancer: Diagnostic and prognostic potential. Clin Transl Oncol. 16:225–233. 2014. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
An F, Liu Y and Hu Y: miR-21 inhibition of LATS1 promotes proliferation and metastasis of renal cancer cells and tumor stem cell phenotype. Oncol Lett 14: 4684-4688, 2017.
APA
An, F., Liu, Y., & Hu, Y. (2017). miR-21 inhibition of LATS1 promotes proliferation and metastasis of renal cancer cells and tumor stem cell phenotype. Oncology Letters, 14, 4684-4688. https://doi.org/10.3892/ol.2017.6746
MLA
An, F., Liu, Y., Hu, Y."miR-21 inhibition of LATS1 promotes proliferation and metastasis of renal cancer cells and tumor stem cell phenotype". Oncology Letters 14.4 (2017): 4684-4688.
Chicago
An, F., Liu, Y., Hu, Y."miR-21 inhibition of LATS1 promotes proliferation and metastasis of renal cancer cells and tumor stem cell phenotype". Oncology Letters 14, no. 4 (2017): 4684-4688. https://doi.org/10.3892/ol.2017.6746
Copy and paste a formatted citation
x
Spandidos Publications style
An F, Liu Y and Hu Y: miR-21 inhibition of LATS1 promotes proliferation and metastasis of renal cancer cells and tumor stem cell phenotype. Oncol Lett 14: 4684-4688, 2017.
APA
An, F., Liu, Y., & Hu, Y. (2017). miR-21 inhibition of LATS1 promotes proliferation and metastasis of renal cancer cells and tumor stem cell phenotype. Oncology Letters, 14, 4684-4688. https://doi.org/10.3892/ol.2017.6746
MLA
An, F., Liu, Y., Hu, Y."miR-21 inhibition of LATS1 promotes proliferation and metastasis of renal cancer cells and tumor stem cell phenotype". Oncology Letters 14.4 (2017): 4684-4688.
Chicago
An, F., Liu, Y., Hu, Y."miR-21 inhibition of LATS1 promotes proliferation and metastasis of renal cancer cells and tumor stem cell phenotype". Oncology Letters 14, no. 4 (2017): 4684-4688. https://doi.org/10.3892/ol.2017.6746
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team